A clinical study comparing different doses of a potential new medicine with an inactive medicine for patients with moderate to severe psoriasis

Phase 1

• Conditions: Plaque Psoriasis; Therapeutic area: Diseases [C] - Immune System Diseases [C20]

• Registration Number: CTIS2023-508992-35-00
• Lead Sponsor: Janssen Cilag International

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-01-16
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Be =18 (or the legal age of consent if it is higher in the jurisdiction in which the study is taking place) years of age at screening, inclusive., Diagnosis of plaque psoriasis, Total BSA =10% at screening and baseline., Total PASI =12 at screening and baseline., Total IGA =3 at screening and baseline.

Exclusion Criteria

Nonplaque form of psoriasis (eg, erythrodermic, guttate, or pustular)., Current drug-induced psoriasis (eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)., A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances., A current diagnosis or history of IBD., Known allergies, hypersensitivity, or intolerance to JNJ-81241459 or its excipients (refer to the JNJ-81241459 IB).

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified